Working… Menu

Bupropion in the Treatment of Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00572234
Recruitment Status : Completed
First Posted : December 12, 2007
Results First Posted : July 26, 2019
Last Update Posted : July 26, 2019
Information provided by (Responsible Party):
Kathleen Grant MD, University of Nebraska

Brief Summary:
Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.

Condition or disease Intervention/treatment Phase
Methamphetamine Use Disorder Drug: bupropion SR Not Applicable

Detailed Description:

Nearly 40% of adults seeking substance use disorders (SUD) treatment in Nebraska report methamphetamine is their drug of choice. In preliminary studies examining bupropion in methamphetamine use, it was well tolerated, reduced craving for methamphetamine and reduced methamphetamine related euphoria. Investigators at the University of Nebraska Medical Center and the University of Nebraska-Lincoln have initiated studies examining bupropion in animals and humans as a potential intervention in addictive disorders. Pre-clinical studies in the Co-Investigator's laboratory were the first to demonstrate the potential utility of bupropion as a pharmacotherapy for methamphetamine use disorders (MUD) while the Principal Investigator studied bupropion as a smoking cessation aid in alcoholics.

The primary goal of this study is to establish an interdisciplinary and translational collaboration to test bupropion in persons in treatment for methamphetamine dependence and to inform pre-clinical studies so as to enhance their practical applicability to clinical settings. The pilot clinical study will examine the treatment effect and safety of a 12 week course of bupropion in persons with methamphetamine use disorder. Concurrently, we will examine the efficacy of bupropion on methamphetamine self-administration in animal models which better simulates clinical approaches.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bupropion in the Treatment of Methamphetamine Dependence
Actual Study Start Date : August 31, 2007
Actual Primary Completion Date : April 6, 2010
Actual Study Completion Date : May 20, 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Experimental: Receiving Bupropion SR
receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
Drug: bupropion SR
12 week course of bupropion SR 150 mg, BID

No Intervention: Treatment as Usual
Not receiving bupropion

Primary Outcome Measures :
  1. Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. [ Time Frame: Assessed Methamphetamine use at weeks 12 and 24, week 24 reported ]
    The primary outcome measure was number of days methamphetamine use/week at weeks 12 and week 24.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient in the substance use disorder program at either the Omaha VA Medical Center or at Catholic Charities Campus for Hope
  • diagnosis of methamphetamine dependence as well as presence or history of psychosis based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria (not to include patients in full sustained remission)
  • provide names, addresses, and phone numbers of at least two collateral informants who can provide information on their methamphetamine and other drug use during follow-up
  • must sign an informed consent as approved by the UNMC Internal Review Board (IRB) and Catholic Charities Research Committee.

Exclusion Criteria:

  • a history of severe injury to their brain
  • advanced cardiac, pulmonary, renal or liver disease
  • predisposition to seizures
  • history of bulimia or anorexia nervosa
  • current diagnosis of major depressive disorder
  • diagnosis or past history of panic disorders, schizophrenia, or bipolar affective disorder
  • family history or childhood history of epilepsy or seizures
  • history of strokes, brain tumors, or bleeding in the brain.
  • used any psychoactive drug within one week of study entry (two weeks for MAO (monoamine oxidase) inhibitors or protriptyline, four weeks for fluoxetine)
  • currently using any theophylline product (e.g. Theodur)
  • used an investigational drug in any study within the past four weeks
  • used a therapeutic course of bupropion SR for > 1 week at any time in the past 12 months or have been evaluated in previous studies examining bupropion SR at anytime
  • If female, the participant must not be pregnant or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00572234

Layout table for location information
United States, Nebraska
Catholic Charities Campus for Hope
Omaha, Nebraska, United States, 68104
Omaha Veterans Affairs Medical Center
Omaha, Nebraska, United States, 68105
Sponsors and Collaborators
University of Nebraska
Layout table for investigator information
Principal Investigator: Kathleen M Grant, MD Omaha Veterans Affairs Medical Center

Layout table for additonal information
Responsible Party: Kathleen Grant MD, Principal Investigator, University of Nebraska Identifier: NCT00572234     History of Changes
Other Study ID Numbers: 260-07-FB
First Posted: December 12, 2007    Key Record Dates
Results First Posted: July 26, 2019
Last Update Posted: July 26, 2019
Last Verified: July 2019
Keywords provided by Kathleen Grant MD, University of Nebraska:
Bupropion SR (Sustained Release)
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Stimulants
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors